



- The sale shall be on "AS IS WHERE IS", "AS IS WHAT IS", "WHATSOEVER IT IS", "WHATEVER THERE IS" and "WITHOUT RECOURSE BASIS" and as such, the sale shall be without any kind of warranties and indemnities.
- The details of the process and timelines are outlined in the E-Auction Process Document, which is available on the website of e-auction service provider Linkstar Infosys Private Limited at <https://eauctions.co.in/>
- Interested bidders shall participate after mandatorily reading and agreeing to the relevant terms and conditions including as prescribed in E-Auction Process Documents and accordingly, submit their expression of interest in the manner prescribed in E-Auction Process Document.
- The Liquidator has the absolute right to accept or reject any or all offer(s) or adjourn/postpone/cancel the e-Auction or withdraw any assets thereof from the auction proceeding at any stage without assigning any reason thereof.
- As per proviso to clause (f) of section 35 of the Code, the interested bidder shall not be eligible to submit a bid if it fails to meet the eligibility criteria as set out in section 29A of the Code (as amended from time to time).

Date and Place: January 14, 2025, Mumbai

Sd/-  
Gaurav Ashok Adukia  
IBBI/IPA-002/IP-N00457/2017-18/11293  
Liquidator of Shivani Trendz Private Limited  
(In Liquidation)  
AFA is Valid till June 30, 2025



## SUDARSHAN PHARMA INDUSTRIES LIMITED

Reg. office: 301, Aura Biplax, Plot no. 7, Above Kalyan Jewellers,  
S. V. Road, Borivali (W), Mumbai 400092

CIN: L51496MH2008PLC184997 Tel: 022 - 4222 1111

Website: [www.sudarshanpharma.com](http://www.sudarshanpharma.com) Email: [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com)

### NOTICE OF EXTRA ORDINARY GENERAL MEETING

Members are requested to note that pursuant to and in compliance with the provisions of Section 110 and all other applicable provisions, if any, of the Companies Act, 2013 read with the applicable Rules framed thereunder including Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 (including any statutory amendment(s), modification(s) or re-enactment(s) thereof, for the time being in force) (the "Act"), General Circular nos. 9/2024 dated September 19, 2024 and the previous circulars on COVID-19 related relaxations issued by Ministry of Corporate Affairs (MCA) applicable in this regard (the "MCA Circulars"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and all other applicable laws, rules and regulations, if any, the Company has sent the Notice of the EGM on 13th January, 2025, through electronic mode only, to those members whose e-mail addresses are registered with the Company / Registrars and Transfer Agent ("RTA"), Kfin Technologies Limited/ Depositories.

Sr. no.	Description of Special Business
1	Issue of 4,30,00,000 Warrants convertible into equity shares on preferential basis to the persons and entities belonging to the promoter and non-promoter category.

In compliance with the MCA Circulars, the Company has completed the dispatch of Notice on Monday, 13th January, 2025 by electronic mode to the Members of the Company holding shares as on Friday, 10th January 2025 ("Cut-off date") and whose email address(es) are registered with the Company / Depository(s) / Depository Participants / Registrar and Transfer Agent - Kfintech Technologies Limited ("Kfintech").

Notice together with explanatory statement and instruction for E-voting is available on the website of the Company at [www.sudarshanpharma.com](http://www.sudarshanpharma.com), on the website of the Stock Exchange where the shares of the Company are listed i.e. BSE Limited at [www.bseindia.com](http://www.bseindia.com) and on the website of National Securities Depository Limited ("NSDL") at [www.evoting.ndsl.com](http://www.evoting.ndsl.com)

The voting rights of members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as of the cut-off date i.e. Tuesday, 28th January, 2025. The remote e-voting period commences on Saturday, 1st February, 2025 at 9.00 a.m. IST and ends on Monday, 3rd February, 2025 at 5.00 p.m. IST. Thereafter, the remote e-voting module shall be disabled for voting by NSDL.

Members whose email address are not registered with Depository Participants (in case of shares held in electronic / dematerialized mode) or with Kfintech (in case of shares held in physical mode) hold shares as on Cut-off date can cast their vote on resolutions proposed in the Notice through E-voting, by following the instructions given in the Notes to the Notice under "Voting through E-Voting" or can contact the Company at [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com)

Members who have not registered / updated their email address(es), are requested to get the same registered / updated with the Company (in case of shares held in physical mode) by writing to the Company at [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com) along with details of folio number, scanned copy of share certificate (front and back) and self-attested copy of PAN card (front and back) or with their Depository Participants (in case of shares held in electronic / dematerialized mode) with whom they maintain their demat accounts.

Details of persons contacted for any issues / queries grievances relating to E-voting:  
NSDL:

Members may refer to the Frequently Asked Questions ("FAQs") and e-voting user manual available at [www.evoting.ndsl.com](http://www.evoting.ndsl.com), under "Help" section or send an email to [evoting@nsdl.com](mailto:evoting@nsdl.com).  
Company:

Mr. Nirav Shah, Company Secretary & Compliance Officer at 301, Aura Biplax, Plot no. 7, Above Kalyan Jewellers, S. V. Road, Borivali (West), Mumbai - 400092 or send an email at [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com) or call at 022 - 4222 1111.

By Order of the Board of Directors  
For, Sudarshan Pharma Industries Limited

Sd/-  
Hemal Mehta  
Chairman & Managing Director  
DIN: 02211121

Date: 13<sup>th</sup> January, 2025  
Place: Mumbai

3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	872.7	1,834.7	5,855.1
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	653.1	1,359.2	4,361.7
5	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	655.2	1,365.1	4,365.0
6	Paid-up equity share capital (face value ₹ 100,000/- each)	1,563.4	1,563.4	1,563.4
7	Reserves (excluding revaluation reserves)	18,585.6	16,569.3	16,957.4
8	Securities Premium Account	-	-	-
9	Net worth	20,149.0	18,132.7	18,520.8
10	Paid up debt capital/outstanding debt	2,87,889.6	2,70,036.1	3,19,581.2
11	Outstanding Redeemable Preference Shares	-	-	-
12	Debt equity ratio	14.3	14.9	17.3
13	Earnings per share (in ₹)	-	-	-
	Basic and diluted EPS	41,774.34	86,938.72	2,78,988.10
14	Capital redemption reserve	466.6	466.6	466.6
15	Debenture redemption reserve	-	-	-
16	Debt Service Coverage Ratio (annualised)	0.23	0.90	0.82
17	Interest Service Coverage Ratio	4.14	8.45	6.21
18	Current ratio	1.08	1.07	1.07
19	Long term debt to working capital ratio	0.21	0.16	0.15
20	Current liability ratio	0.98	0.99	0.99
21	Total debts to Total Assets ratio	0.81	0.81	0.89
22	Debtors turnover (in times) (annualised)	3.96	16.68	16.70
23	Capital to Risk-Weighted Assets Ratio (CRAR) %	31.3%	29.1%	26.6%
24	Operating margin %	14.6%	27.5%	22.3%
25	Net profit margin %	10.9%	20.4%	16.6%

1 The above is an extract of the detailed format of quarterly financial results filed with the Bombay Stock Exchange under regulation 52 of the Listing Regulations. The full format of the quarterly financial results is available on the websites of the Bombay Stock Exchange ([www.bseindia.com](http://www.bseindia.com)) and the Company ([www.icicisecuritiespd.com](http://www.icicisecuritiespd.com)).

2 For the other line items referred in regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Bombay Stock Exchange and can be accessed on the URL ([www.bseindia.com](http://www.bseindia.com)).

3 The financial results have been approved by the Board of Directors at its meeting held on January 13, 2025.

4 The Auditors' Report on the financial statements of the Company for the period ended December 31, 2024 is unqualified.

5 The financial statements have been prepared as per the format prescribed in Division III of Schedule III of the Companies Act, 2013.

6 The financial results have been prepared in accordance with the recognition and measurement principles of IND AS prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder and other accounting principles generally accepted in India.

7 There is no separate reportable segment for the Company as per INDAS 108 - 'Operating Segments'.

8 There have been no deviations in the use of proceeds of issue of debt securities from the objects stated in the offer document.

9 The Board of Directors at its meeting held on April 19, 2024 had recommended final dividend on equity shares amounting to ₹ 1,699.4 million (₹ 108,700/- per equity share) for the year ended March 31, 2024. The same was approved by shareholders in annual general meeting held on August 20, 2024. This dividend was paid on August 23, 2024.

10 The Board of Directors at its meeting held on October 18, 2024 have approved the first interim dividend of ₹ 890.0 million (₹ 56,930/- per equity share) for the period ended September 30, 2024 (₹ 300.2 million for the period ended September 30, 2023). This dividend was paid on October 23, 2024.

11 The Board of Directors at its meeting held on January 13, 2025 have approved the second interim dividend of ₹ 890.0 million (₹ 56,930/- per equity share) for the period ended December 31, 2024 (₹ 600.3 million for the period ended December 31, 2023).

12 Given the nature of business of the Company, the inventory turnover ratio is not applicable. The Company reports Capital to risk weighted assets ratio (CRAR) to Reserve Bank of India as per guidelines applicable to Primary Dealers. The same has been disclosed in lieu of inventory turnover ratio.

For and on behalf of the Board of Directors

Shallendra Jhingam  
Managing Director & CEO

Mumbai, January 13, 2025

rediffusion.in